Combining acid ceramidase and Bcl-2 inhibition to treat acute myeloid leukemia
Mechanisms and In Vivo Efficacy of Synergistic Acid Ceramidase and Bcl-2 Inhibition in Acute Myeloid Leukemia
This study is looking at a new way to treat acute myeloid leukemia (AML) by using a combination of two medications to see if they can work better together, especially for patients who can’t handle regular chemotherapy.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Virginia NIH-funded |
| Lab location | 1 site (Charlottesville, United States) |
| Project ID | NIH-11179104 on NIH RePORTER |
What this research studies
This research investigates a new treatment approach for acute myeloid leukemia (AML) by combining an acid ceramidase inhibitor with venetoclax, a Bcl-2 antagonist. The study aims to understand how this combination can enhance the effectiveness of existing therapies, particularly for patients who cannot tolerate standard chemotherapy. By targeting specific metabolic pathways and survival proteins in AML cells, the research seeks to improve patient outcomes and reduce relapse rates. Patients may be involved in trials assessing the safety and efficacy of this novel treatment strategy.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with acute myeloid leukemia who are unable to tolerate standard induction chemotherapy.
Not a fit: Patients with other types of leukemia or those who have already received extensive treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients with acute myeloid leukemia, potentially improving survival rates and reducing the likelihood of relapse.
How similar studies have performed: Previous research has shown promising results with similar approaches targeting metabolic pathways in cancer treatment, indicating potential for success in this novel combination.
Where this research is happening
Charlottesville, United States
- University of Virginia — Charlottesville, United States (Active)
Researchers
- Principal investigator: Ung, Johnson — University of Virginia
- Study coordinator: Ung, Johnson
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.